News Snapshot:
Chinese clinical-stage drug developer, Kintor Pharmaceutical Ltd, has announced the initiation of the Phase III clinical trial of proxalutamide for hospitalised COVID-19 patients in the US. The first patient has already been dosed, according to Global Banking and Finance. Proxalutamide is a nonsteroidal antiandrogen that is under development for the potential treatment of COVID-19, among other diseases, including prostate cancer and breast cancer. Proxalutamide promotes the clearance of pathogens and decreases inflammation by activating the Nrf2 pathway, and reduces the intensity of the cytokine response, which would be of clinical benefit to patients with COVID-19. Kintor’s Phase III trial is...
